These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 11110737)

  • 1. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.
    Wilcock GK; Lilienfeld S; Gaens E
    BMJ; 2000 Dec; 321(7274):1445-9. PubMed ID: 11110737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
    Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
    J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
    Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
    Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galantamine for vascular cognitive impairment.
    Craig D; Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD004746. PubMed ID: 16437493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.
    Rockwood K; Fay S; Song X; MacKnight C; Gorman M;
    CMAJ; 2006 Apr; 174(8):1099-105. PubMed ID: 16554498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
    Erkinjuntti T; Kurz A; Gauthier S; Bullock R; Lilienfeld S; Damaraju CV
    Lancet; 2002 Apr; 359(9314):1283-90. PubMed ID: 11965273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.
    Raskind MA; Peskind ER; Wessel T; Yuan W
    Neurology; 2000 Jun; 54(12):2261-8. PubMed ID: 10881250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.
    Burns A; Bernabei R; Bullock R; Cruz Jentoft AJ; Frölich L; Hock C; Raivio M; Triau E; Vandewoude M; Wimo A; Came E; Van Baelen B; Hammond GL; van Oene JC; Schwalen S
    Lancet Neurol; 2009 Jan; 8(1):39-47. PubMed ID: 19042161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A naturalistic study of galantamine for Alzheimer's disease.
    Brodaty H; Woodward M; Boundy K; Barnes N; Allen G;
    CNS Drugs; 2006; 20(11):935-43. PubMed ID: 17044730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.
    Suh GH; Yeon Jung H; Uk Lee C; Hoon Oh B; Nam Bae J; Jung HY; Ju YS; Kil Yeon B; Park J; Hong I; Choi S; Ho Lee J;
    Clin Ther; 2004 Oct; 26(10):1608-18. PubMed ID: 15598477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine for vascular cognitive impairment.
    Birks J; Craig D
    Cochrane Database Syst Rev; 2006 Jan; (4):CD004746. PubMed ID: 23862185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galantamine for Alzheimer's disease.
    Loy C; Schneider L
    Cochrane Database Syst Rev; 2004 Oct; (4):CD001747. PubMed ID: 15495017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
    Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
    Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.
    Tariot PN; Solomon PR; Morris JC; Kershaw P; Lilienfeld S; Ding C
    Neurology; 2000 Jun; 54(12):2269-76. PubMed ID: 10881251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
    Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
    J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.